Moody Aldrich Partners LLC Halozyme Therapeutics, Inc. Transaction History
Moody Aldrich Partners LLC
- $503 Million
- Q3 2024
A detailed history of Moody Aldrich Partners LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 110,558 shares of HALO stock, worth $5.23 Million. This represents 1.26% of its overall portfolio holdings.
Number of Shares
110,558
Previous 135,512
18.41%
Holding current value
$5.23 Million
Previous $7.1 Million
10.85%
% of portfolio
1.26%
Previous 1.5%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$834 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$610 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$314 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$192 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$161 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.59B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...